IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Endologix Inc. & Advises Investors with Losses to Conta...
November 17 2016 - 2:24PM
Business Wire
Lundin Law PC, a shareholder rights firm, announces that it is
investigating claims against Endologix Inc. (“Endologix” or the
“Company”) (Nasdaq: ELGX) concerning possible violations of federal
securities laws.
To get more information about this investigation, please contact
Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via
email at brian@lundinlawpc.com.
On August 2, 2016, CEO John McDermott stated that Endologix
would seek approval of the original version of the Nellix system
that was used in the Nellix investigational device exemption
(“IDE”) clinical trial, the EVAS FORWARD-IDE Study, given since
Endologix had the needed clinical data. On November 16, 2016,
Endologix announced that the U.S. Food & Drug Administration
requested two-year follow-up data on patients enrolled in the
EVAS-FORWARD-IDE study to assess Nellix. When this news was
announced, the stock price of Endologix declined.
Lundin Law PC was created by Brian Lundin, a securities
litigator based in Los Angeles, dedicated to upholding
shareholders’ rights.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161117006232/en/
Lundin Law PCBrian Lundin, Esq.Telephone: 888-713-1033Facsimile:
888-713-1125brian@lundinlawpc.comhttp://lundinlawpc.com/
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Apr 2023 to Apr 2024